Posts tagged Celgene
Roth ups Evotec price target to €16

Roth Capital Partners raised its price target for “buy-rated Evotec AG (FSE:EVT) to €16 from €5.50, reflecting a review of the company’s partnered pipeline assets. The stock was recently quoted at €11.66.

Read More
Vital Therapies names Faheem Hasnain as a director

Vital Therapies (NASDAQ:VTL) appointed Faheem Hasnain to the board, effective immediately.

Mr. Hasnain served as president, CEO and as a director of Receptos from November 2010 to August 2015, when it was purchased by Celgene for $7.8-billion. He is currently chairman of Tocagen and Sente.

Read More